Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review

Authors

  • Tracy Anabella Hermansyah Faculty of Medicine Universitas Indonesia, Jakarta, Indonesia
  • Eka Ginanjar Division of Cardiovascular, Department of Internal Medicine Faculty of Medicine Universitas Indonesia - Cipto Mangunkusumo Hospital, Jakarta, Indonesia
  • Valerie Hirsy Putri Bunda General Hospital, Jakarta, Indonesia

Keywords:

COVID-19, myocardial injury, troponin, BNP, NT-proBNP, prognostic factors

Abstract

Background: This study aimed to summarize the prognosis of Corona Virus Disease 2019 (COVID-19) patients with elevated troponin and N-terminal pro brain natriuretic peptide (NT-proBNP) levels and demonstrate the involvement of myocardial injury as a complication in COVID-19. Methods: A systematic literature search was performed using several databases (PubMed, MEDLINE, PROQUEST and SCOPUS ) for studies published up to August 2020. Observational studies about the mortality outcome of COVID-19 patients who experienced cardiac injury, as defined by the elevation of serum levels of troponin, brain natriuretic peptide (BNP), with NT-proBNP or only BNP or only NT-proBNP, were included. In addition, a critical appraisal was conducted for all included studies using the Critical Appraisal for Prognostic Studies checklist published by the Centre for Evidence-Based Medicine by the University of Oxford. Results: Seven retrospective observational studies fulfilled the inclusion criteria. This study found that there is a higher risk of death in COVID 19 patients with higher levels of troponin and NT-proBNP, indicating the importance of these biomarkers as determinant factors to predict in-hospital deaths. Conclusion: Based on the analysis, elevation of troponin  and NT-proBNP levels plays an essential role in determining the patient prognosis because it is shown to be associated with in-hospital mortality. This also supports the involvement of myocardial injury as a prominent fatal complication in COVID-19.

References

Atri D, Siddiqi HK, Lang J, Nauffal V, Morrow DA, Bohula EA. COVID-19 for the Cardiologist: A current review of the virology, clinical epidemiology, cardiac and other clinical manifestations and potential therapeutic strategies. JACC: Basic to Translational Science. 2020. doi: https://doi.org/10.1016/j.jacbts.2020.04.002.

Mason RJ. Pathogenesis of COVID-19 from a cell biology perspective. Eur Respir J. 2020;55(4):2000607. Published 2020 Apr 16. doi:10.1183/13993003.00607-2020

WHO. Coronavirus disease 2019 (COVID-19) Situation Report – 97. Geneva, Switzerland. WHO; 2020. Accessed at 26/04/2020. Cited from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200426-sitrep-97-COVID-19.pdf?sfvrsn=d1c3e800_6

Zeng JH, Liu YX, Yuan J, et al. First case of COVID-19 complicated with fulminant myocarditis: a case report and insights [published online ahead of print, 2020 Apr 10]. Infection. 2020;1-5. doi:10.1007/s15010-020-01424-5

Rizzo P, Vieceli Dalla Sega F, Fortini F, Marracino L, Rapezzi C, Ferrari R. COVID-19 in the heart and the lungs: could we «Notch» the inflammatory storm?. Basic Res Cardiol. 2020;115(3):31. Published 2020 Apr 9. doi:10.1007/s00395-020-0791-5

Zheng Y., Ma Y., Zhang J, et al. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259–60 (2020). https://doi.org/10.1038/s41569-020-0360-5

Hua A, O’Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19 [published online ahead of print, 2020 Mar 30]. Eur Heart J. 2020;ehaa253. doi:10.1093/eurheartj/ehaa253

Hu H, Ma F,Wei X, Fang Y. Coronavirus fulminant myocarditis treated with glucocorticoid and human immunoglobulin, European Heart Journal. 2020, ehaa190. https://doi.org/10.1093/eurheartj/ehaa190

Gao et al. Role of Troponin I Proteolysis in the Pathogenesis of Stunned Myocardium. AHA J. 2020;80(3):393-9. https://doi.org/10.1161/01.res.0000435855.49359.47

Sharma S, Jackson PG, Makan J. Cardiac troponins. J Clin Pathol. 2004;57(10):1025-6. doi:10.1136/jcp.2003.015420

Babapoor-Farrokhran S, Gill D, Walker J, Rasekhi RT, Bozorgnia B, Amanullah A. Myocardial injury and COVID-19: Possible mechanisms. Life Sci. 2020;253:117723. doi:10.1016/j.lfs.2020.117723

Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease [published online ahead of print, 2020 Mar 21]. Circulation. 2020;10.1161/CIRCULATIONAHA.120.046941.

Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6(7):e1000100. doi:10.1371/journal.pmed.1000100

Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study [published correction appears in Lancet. 2020;395(10229):1038] [published correction appears in Lancet. 2020 Mar

Chen Tao, Wu Di, Chen Huilong, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368

Stefanini, et al. Early detection of elevated cardiac biomarkers to optimise risk stratification in patients with COVID-19. Heart. 2020;106:1512–8.

Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with Coronavirus Disease 2019 (COVID-19) [published online ahead of print, 2020 Mar 27]. JAMA Cardiol. 2020;e201017. doi:10.1001/jamacardio.2020.1017

Gao L., Jiang D., Wen X, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21:83. https://doi.org/10.1186/s12931-020-01352-w

Zhang, et al. Myocardial injury is associated with in-hospital mortality of confirmed or suspected COVID-19 in Wuhan, China: A single center retrospective cohort study

Preprint medRxiv. 2020. doi: https://doi.org/10.1101/2020.03.21.20040121.

Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. Published online March 25, 2020. doi:10.1001/jamacardio.2020.0950

Downloads

Published

2022-01-10

How to Cite

Hermansyah, T. A., Ginanjar, E., & Putri, V. H. (2022). Elevation of Cardiac Biomarkers in COVID-19 As a Major Determinant for Mortality: A Systematic Review. Acta Medica Indonesiana, 53(4), 385. Retrieved from http://www.actamedindones.org/index.php/ijim/article/view/1597

Issue

Vol. 53 No. 4 (2021): Acta Medica Indonesiana

Section

ORIGINAL ARTICLE

License

Copyright

The authors who publish in this journal agree to the following requirements:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a  Creative Commons Attribution 4.0 International License (CC BY 4.0) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors can enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) before and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work. (See The Effect of Open Access)

Privacy Statement

The names and email addresses entered in this journal site will be used exclusively for the stated purposes of this journal and will not be made available for any other purpose or to any other party.

Most read articles by the same author(s)

1 2 > >>